21.10.2010 • NewsEuropean Uniongeneric drugsgenerics

EU To Seek Details Of Deals Delaying Generic Drugs

EU antitrust regulators plan to review drug patent settlements struck this year to delay cheaper generics going to market, as part of their crackdown on illegal deals, a senior European Commission official said on Wednesday.

"We will probably carry out another monitoring exercise at the beginning of 2011, covering January 2010 to December 2010," Dominik Schnichels, who heads the European Commission's pharmaceuticals taskforce, told a competition conference. In a critical report on the sector in July last year, the Commission vowed to pursue drugmakers suspected of anticompetitive acts after an investigation found such delays had cost healthcare providers and consumers billions of euros.

It later started probes into privately owned drugmaker Servier and several firms that make generic drugs and also raided several drugmakers, including Sanofi-Aventis, Novartis and Teva Pharmaceutical Industries.

In January this year, the EU watchdog sought details of deals between originator and generic pharmaceutical companies from July 2008 to December 2009. Its report showed there were fewer anticompetitive agreements.

"We need to see if the positive trends we have observed continue," Schnichels said at the conference, which was organized by the Global Competition Review.

U.S. lawmakers are also tackling the issue.

Interview

Specialty Chemicals in a Shifting World
Adapting to Tariffs and Strengthening Regional Networks

Specialty Chemicals in a Shifting World

Jennifer Abril, President & CEO of SOCMA, discusses the impact of new tariffs and the importance of regional supply networks in the specialty chemical industry.

Virtual Event

Digitalization in the Chemical Industry
CHEManager Spotlight

Digitalization in the Chemical Industry

Save the Date: October 22, 2025
The event will be promoted to a combined audience of over 100,000 professionals across Europe through the CHEManager and CITplus networks.